GLP-1 Heart Benefits May Not Last: What the New Study Means for Patients

GLP-1 Heart Benefits May Not Last: What the New Study Means for Patients

For many patients, the decision to start a GLP-1 medication is about more than just weight loss. These medications have proven cardiovascular benefits too. If you have type 2 diabetes, obesity, or other metabolic conditions, a GLP-1 receptor agonist may reduce your risk of heart attacks, strokes, and other major cardiac events.

But what happens if you need to stop treatment?

A new study published in March 2026 in BMJ Medicine has found something important: the heart benefits from GLP-1 medications like semaglutide and tirzepatide begin to fade within months of stopping treatment. Within six months, heart risks start creeping back up. By a year and a half after discontinuation, the cardiovascular protection patients worked so hard to achieve may be almost completely erased.

For patients considering GLP-1 treatment, or those who may need to stop soon because of cost, side effects, or insurance barriers, this study offers a critical piece of the puzzle. It reinforces what obesity and diabetes specialists have been saying for years: these medications often work best when they are part of a long-term treatment plan, not a temporary fix.

If you are worried about losing heart benefits after stopping a GLP-1, or if you are thinking about discontinuation for any reason, this article will help you understand what the latest research means for your health.

What the March 2026 study found

The study came from researchers at Washington University School of Medicine in St. Louis, led by Dr. Ziyad Al-Aly, a clinical epidemiologist. The team analyzed medical records from more than 333,000 patients with type 2 diabetes who were treated through the Veterans Health Administration.

This was not a controlled clinical trial. It was a real-world data analysis, which makes it especially valuable. Real life is messy. Patients stop and restart medications. Insurance changes. Side effects happen. Supply issues interrupt treatment. Life stress, travel, illness, and access to follow-up all affect outcomes.

The researchers compared roughly 132,000 patients who had been prescribed GLP-1 medications to more than 201,000 others who had been prescribed a different type of diabetes medication called sulfonylureas.

The GLP-1s included in the study were:

• Semaglutide (Ozempic, Wegovy)
• Tirzepatide (Mounjaro, Zepbound)
• Liraglutide (Victoza)
• Exenatide (Byetta, Bydureon BCise)
• Dulaglutide (Trulicity)

The heart benefits were real—while patients stayed on treatment

Patients who took GLP-1 medications continuously for an average of three years without stopping saw the biggest heart health benefits. They had about an 18% lower risk of heart attacks, strokes, or death compared to people who were on sulfonylureas.

That level of protection is very close to what the landmark SELECT trial found for semaglutide in 2023, where the risk of major cardiovascular events was reduced by an average of 20% in people taking semaglutide for obesity.

Importantly, the SELECT trial also found that heart benefits occurred even in people who did not lose weight on semaglutide. This suggests there are both weight-dependent and weight-independent effects on the heart.

But the benefits faded fast after stopping

Among those taking GLP-1s, the study further compared patients who stopped using the medications to those who stayed on them continuously for three years.

The results were striking:

• 6 months after stopping: Heart risks increased by 4%
• 1 year after stopping: Heart risks increased by 14%
• 1.5 years after stopping: Heart risks increased by 22%

By the 18-month mark, the cardiovascular protection they had gained was virtually erased.

Dr. Al-Aly described this as a kind of "metabolic whiplash." He noted that it takes much longer to build cardiovascular benefit than it does to lose it.

"It takes a whole lot longer to build or accrue benefit, and then half as much to erase all that benefit. For example, what took three years to build — three years of the cardiovascular benefit — was actually erased or undone with just one and a half years of stopping."

This is not to say that patients who stop treatment are worse off than if they had never started. But they are worse off than if they had stayed on the medication.

Why this matters for semaglutide and tirzepatide patients

This study focused on patients with type 2 diabetes, but the findings have clear implications for anyone taking semaglutide or tirzepatide for weight loss, metabolic health, or cardiovascular risk reduction.

1. GLP-1 medications are not "jump-start" therapies for many people

One common misconception is that GLP-1 medications can help you lose weight and improve your health, and then you can stop and maintain those benefits on your own.

For some people, that may be possible. But for many others, especially those with chronic metabolic conditions, stopping the medication can mean losing much of the progress.

This study adds to the growing body of evidence that GLP-1 medications often work best as ongoing treatment, not short-term intervention.

2. The cardiovascular benefits are real—but they require continued use

If your doctor prescribed a GLP-1 in part to reduce your risk of heart attacks, strokes, or other cardiac events, this study underscores the importance of staying on treatment if possible.

The cardiovascular protection is not just a bonus feature. For patients with type 2 diabetes, obesity, or metabolic syndrome, heart disease is one of the leading causes of death. A 20% reduction in major cardiovascular events is clinically meaningful.

But if the medication is stopped, that protection may fade faster than it was built.

3. Cost and access barriers are putting patients at risk

Many patients do not stop GLP-1 medications because they want to. They stop because:

• Insurance denials or prior authorization failures make the medication unaffordable
• Employer plan changes eliminate coverage for weight-loss uses
• Drug shortages or pharmacy supply interruptions force patients off treatment
• Side effects like nausea, vomiting, or fatigue make it hard to continue
• Out-of-pocket costs become unsustainable, especially for patients without insurance

Studies show that roughly half of people who start taking GLP-1 drugs will stop within one year, with cost and side effects being the two biggest reasons.

When insurers deny coverage or force patients to stop after they meet their weight loss goals, they may be inadvertently increasing those patients' cardiovascular risk.

How GLP-1 medications protect the heart (and why stopping matters)

The exact mechanisms by which GLP-1 medications improve cardiovascular health are still being studied, but researchers have identified several likely pathways:

1. Weight loss reduces inflammation

Many patients lose significant weight on GLP-1 medications. Weight loss itself can reduce systemic inflammation, lower blood pressure, improve cholesterol levels, and reduce strain on the heart.

When patients stop the medication and regain weight, those inflammatory and metabolic pressures may return.

2. Direct effects on heart tissue

The heart has GLP-1 receptors. This means the medication may have a direct effect on heart tissue, independent of weight loss.

Some studies suggest GLP-1 medications may improve endothelial function (the health of blood vessel linings), reduce arterial stiffness, and improve heart muscle function.

When the medication is stopped, these direct effects may be lost.

3. Improved insulin sensitivity and glucose control

For patients with type 2 diabetes or prediabetes, GLP-1 medications improve insulin sensitivity and help stabilize blood sugar levels.

High blood sugar over time damages blood vessels and increases the risk of heart disease. When patients stop treatment, blood sugar control may worsen again, increasing cardiovascular risk.

4. Reduced appetite and improved eating patterns

GLP-1 medications help regulate hunger and fullness signals. Many patients report eating less, having fewer cravings, and making healthier food choices while on treatment.

When the medication is stopped, appetite may return to baseline or higher, making it harder to maintain healthy eating patterns. This can contribute to weight regain and worsening metabolic health.

What to do if you need to stop a GLP-1 medication

If you are considering stopping semaglutide, tirzepatide, or another GLP-1 medication, here are some strategies that may help protect your cardiovascular health:

1. Talk to your doctor before stopping, if possible

Do not stop cold turkey without discussing it with your prescribing clinician. They may be able to:

• Adjust your dose to reduce side effects
• Switch you to a different GLP-1 medication
• Help you appeal an insurance denial
• Suggest compounded alternatives if cost is an issue
• Build a maintenance plan around nutrition, exercise, and follow-up

If you need help finding a clinic that supports long-term GLP-1 treatment with cardiac monitoring, our clinic finder can help.

2. Consider whether tapering makes sense

Some clinicians recommend a slow taper rather than stopping abruptly. This may give your body time to adjust and may reduce the severity of rebound hunger or metabolic changes.

Tapering is not right for everyone, and it should be guided by your prescribing clinician. But it is a conversation worth having.

3. Prioritize cardiovascular health through lifestyle

If you do stop treatment, focus on protecting your heart through:

• Regular cardiovascular exercise (walking, cycling, swimming, strength training)
• Heart-healthy eating patterns (high in fiber, lean protein, vegetables; low in processed foods and added sugars)
• Blood pressure monitoring and management
• Cholesterol management (medication if needed)
• Blood sugar monitoring if you have diabetes or prediabetes
• Stress management and adequate sleep

These strategies will not fully replace the cardiovascular benefits of GLP-1 medication, but they can help reduce risk.

4. Consider alternative medications

If cost is the issue, ask your doctor about:

• Compounded semaglutide or compounded tirzepatide (often more affordable than brand-name options, though subject to regulatory uncertainty)
• Switching to an older, less expensive GLP-1 like liraglutide (Victoza)
• Other weight-loss or diabetes medications that may have some cardiovascular benefit

If insurance is the barrier, your doctor may be able to help you appeal the denial or provide documentation of medical necessity.

5. Monitor your cardiovascular risk closely

If you stop a GLP-1 medication, work with your doctor to monitor your cardiovascular risk markers closely:

• Blood pressure
• LDL cholesterol and triglycerides
• Hemoglobin A1c (if you have diabetes)
• Body weight and waist circumference
• Symptoms like chest pain, shortness of breath, or fatigue

Early detection of worsening risk can help you and your doctor intervene before a serious cardiac event occurs.

Comparing semaglutide vs tirzepatide for cardiovascular health

The study did not break down results separately for semaglutide vs tirzepatide, but both medications have shown cardiovascular benefits in prior research.

Semaglutide cardiovascular data

The SELECT trial (published in 2023) found that semaglutide reduced the risk of major adverse cardiovascular events by 20% in people with obesity and existing cardiovascular disease, even in those who did not lose significant weight.

Tirzepatide cardiovascular data

However, large dedicated cardiovascular outcome trials for tirzepatide are still ongoing.

For a detailed comparison of these two medications, including dosing, side effects, and cost, see our guide: Semaglutide vs Tirzepatide.

Why insurers and policymakers need to pay attention

Dr. Al-Aly and other experts have emphasized that insurers need to understand the evolving evidence for GLP-1 medications.

When insurers deny coverage after a patient reaches their weight loss goal, they may be exposing that patient to unnecessary cardiovascular risk.

"Stopping has consequences to the heart. Insurers need to realize that when they deny these things, they are actually exposing people to unnecessary risk."

This is especially important for patients with:

• Type 2 diabetes
• Obesity
• Existing cardiovascular disease
• Metabolic syndrome
• Multiple cardiovascular risk factors

For these patients, GLP-1 medications may need to be treated as chronic disease management, not cosmetic intervention.

Questions this study leaves unanswered

While this study is one of the largest and most rigorous analyses of cardiovascular outcomes after stopping GLP-1 medications, it does leave some questions open:

1. What if you maintain your weight loss after stopping?

The study did not track whether patients who maintained their weight loss after stopping continued to see cardiovascular benefits.

It is possible that patients who successfully keep the weight off through diet, exercise, and lifestyle changes may retain some heart health benefits.

But given the complex metabolic effects of GLP-1 medications, weight maintenance alone may not be enough to preserve all the cardiovascular protection.

2. Does maintenance dosing help?

Some clinicians use lower "maintenance doses" of GLP-1 medications after patients reach their weight loss goal.

It is not yet clear whether maintenance dosing can preserve cardiovascular benefits while reducing cost and side effects.

More research is needed.

3. What about people using GLP-1s only for weight loss?

This study focused on patients with type 2 diabetes. It is not yet clear whether the same patterns hold for people using GLP-1 medications solely for weight loss without diabetes.

However, given the known cardiovascular benefits of weight loss and the direct effects of GLP-1s on heart tissue, it is reasonable to assume similar risks apply.

The bottom line

The new 2026 study from Washington University adds an important piece to the growing body of evidence on GLP-1 medications and cardiovascular health.

Key takeaways:

• GLP-1 medications like semaglutide and tirzepatide reduce the risk of heart attacks, strokes, and other major cardiovascular events by about 18-20% in patients with diabetes and obesity.
• Those benefits begin to fade within 6 months of stopping treatment.
• By 18 months after discontinuation, most of the cardiovascular protection is lost.
• For many patients, GLP-1 medications may work best as long-term treatment, not short-term intervention.
• If you need to stop, talk to your doctor first to create a plan that protects your heart health.

If you are considering starting a GLP-1 medication, or if you are worried about stopping, now is the time to have an honest conversation with your doctor about:

• Your cardiovascular risk
• Your treatment goals
• How long you may need to stay on treatment
• What happens if you need to stop
• How to protect your heart health if discontinuation becomes necessary

Find a clinic that monitors cardiac health

Not all GLP-1 clinics provide the same level of cardiovascular monitoring and follow-up care.

If heart health is a priority for you, look for a clinic that:

• Offers baseline and ongoing cardiovascular risk assessments
• Monitors blood pressure, cholesterol, and blood sugar regularly
• Has a plan for long-term treatment, not just short-term weight loss
• Can help you navigate insurance appeals or find affordable alternatives if needed

Use our clinic finder to browse GLP-1 providers in your area and compare their services, pricing, and patient reviews.

This article is for informational purposes only. Always consult a licensed healthcare provider before starting, stopping, or changing any medication.